JW LIFESCIENCE Announces Shareholder Return Policy with 25% Payout Target and 10-Year Consecutive Dividends, Alongside Governance Improvement Efforts
FY2025 consolidated revenue of 257.8B KRW, operating profit 33.2B KRW, net income 28.6B KRW, with revenue growth (+15.9% YoY) but net profit decline (-35%).
Year-end dividend of 550 KRW per share (dividend yield 4.4%), 10 consecutive years of dividends. Consolidated payout ratio 29.77%.
In March 2026, disclosed a value-up plan targeting a consolidated payout ratio of around 25% for 2026-2028.
Largest shareholder JW Holdings holds 42.98%, minority shareholders 48.85%. No dilutive securities (CB, BW, EB) outstanding.
Board consists of 3 inside directors and 2 outside directors, 100% attendance. Internal audit by a full-time auditor (not accounting/finance expert).
Compliance rate of 9 out of 15 core governance indicators (60%). Non-compliance items: CEO succession plan, internal control policy, independent board chair, cumulative voting, etc.
Internal control and risk management policies not formalized, but compliance and internal accounting management systems are in place.
No designation as an unfaithful disclosure entity during the period. External auditor: Han Young Accounting Corp. (2025), unqualified opinion.
[AI Summary]This disclosure reflects stable governance with no major positive or negative catalysts. Enhanced dividend policy is positive, but governance gaps (succession, internal controls) require monitoring. Limited short-term stock impact.